Furthermore, acquired resistance to immunotherapies, as represented by the loss of MHC molecules and clonal neoantigens in tumor cells, is also emerging as a significant clinical obstacle (McGranahan and Swanton, 2019). Here, HLA-C is linked to neoplasm.